| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 93 | 2024 | 603 | 7.050 |
Why?
|
| Mice, SCID | 84 | 2023 | 506 | 4.120 |
Why?
|
| Mice, Inbred NOD | 90 | 2024 | 511 | 4.070 |
Why?
|
| Insulin-Secreting Cells | 28 | 2024 | 177 | 3.830 |
Why?
|
| T-Lymphocytes | 84 | 2023 | 968 | 3.820 |
Why?
|
| Disease Models, Animal | 71 | 2023 | 2084 | 3.620 |
Why?
|
| Islets of Langerhans Transplantation | 38 | 2024 | 170 | 3.380 |
Why?
|
| Mice | 234 | 2024 | 10318 | 3.240 |
Why?
|
| Islets of Langerhans | 38 | 2024 | 267 | 3.230 |
Why?
|
| Skin Transplantation | 35 | 2010 | 152 | 3.100 |
Why?
|
| Transplantation Tolerance | 18 | 2012 | 65 | 2.960 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 21 | 2022 | 76 | 2.930 |
Why?
|
| Animals | 352 | 2024 | 19740 | 2.900 |
Why?
|
| Graft Survival | 36 | 2020 | 279 | 2.570 |
Why?
|
| Transplantation, Heterologous | 36 | 2020 | 223 | 2.460 |
Why?
|
| Membrane Glycoproteins | 47 | 2011 | 668 | 2.320 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 19 | 2017 | 328 | 1.990 |
Why?
|
| Thymus Gland | 41 | 2024 | 222 | 1.960 |
Why?
|
| Hematopoietic Stem Cells | 22 | 2017 | 274 | 1.910 |
Why?
|
| Rats | 133 | 2024 | 1918 | 1.820 |
Why?
|
| Mice, Transgenic | 35 | 2024 | 1226 | 1.750 |
Why?
|
| Leukocytes, Mononuclear | 14 | 2023 | 238 | 1.750 |
Why?
|
| Graft Rejection | 27 | 2020 | 260 | 1.700 |
Why?
|
| Antibodies, Monoclonal | 56 | 2020 | 857 | 1.700 |
Why?
|
| CD8-Positive T-Lymphocytes | 37 | 2024 | 647 | 1.570 |
Why?
|
| Diabetes Mellitus, Experimental | 37 | 2021 | 194 | 1.550 |
Why?
|
| ADP Ribose Transferases | 25 | 2006 | 62 | 1.500 |
Why?
|
| Lymphocyte Activation | 37 | 2020 | 739 | 1.480 |
Why?
|
| Mice, Knockout | 40 | 2024 | 1997 | 1.430 |
Why?
|
| Rats, Inbred BB | 54 | 2017 | 134 | 1.420 |
Why?
|
| Hematopoiesis | 17 | 2014 | 123 | 1.400 |
Why?
|
| Spleen | 53 | 2016 | 486 | 1.340 |
Why?
|
| Autoimmune Diseases | 27 | 2006 | 224 | 1.310 |
Why?
|
| Transplantation Chimera | 7 | 2012 | 37 | 1.300 |
Why?
|
| Receptors, Interleukin-2 | 15 | 2015 | 70 | 1.200 |
Why?
|
| Mice, Inbred C57BL | 70 | 2024 | 3211 | 1.160 |
Why?
|
| CD40 Ligand | 36 | 2013 | 155 | 1.160 |
Why?
|
| Transplantation, Homologous | 26 | 2010 | 234 | 1.120 |
Why?
|
| Salmonella typhi | 5 | 2024 | 19 | 1.110 |
Why?
|
| Graft vs Host Disease | 11 | 2018 | 99 | 1.090 |
Why?
|
| Autoimmunity | 19 | 2012 | 221 | 1.070 |
Why?
|
| Cord Blood Stem Cell Transplantation | 5 | 2016 | 19 | 1.040 |
Why?
|
| Histocompatibility Antigens | 25 | 2001 | 107 | 1.030 |
Why?
|
| Toll-Like Receptors | 8 | 2013 | 434 | 1.010 |
Why?
|
| Immune Tolerance | 18 | 2018 | 169 | 1.010 |
Why?
|
| Typhoid Fever | 5 | 2024 | 21 | 0.990 |
Why?
|
| Signal Transduction | 32 | 2024 | 2891 | 0.970 |
Why?
|
| Mice, Inbred BALB C | 37 | 2011 | 880 | 0.960 |
Why?
|
| Humans | 161 | 2024 | 60107 | 0.950 |
Why?
|
| Immunity, Innate | 23 | 2023 | 768 | 0.940 |
Why?
|
| Immune System | 10 | 2023 | 129 | 0.920 |
Why?
|
| T-Lymphocyte Subsets | 20 | 2017 | 236 | 0.890 |
Why?
|
| Isoantigens | 19 | 2016 | 71 | 0.880 |
Why?
|
| Antibodies | 6 | 2013 | 176 | 0.870 |
Why?
|
| Killer Cells, Natural | 17 | 2022 | 214 | 0.860 |
Why?
|
| Cell Differentiation | 29 | 2018 | 1297 | 0.850 |
Why?
|
| Lymphocyte Depletion | 24 | 2006 | 95 | 0.850 |
Why?
|
| Genetic Predisposition to Disease | 18 | 2023 | 678 | 0.850 |
Why?
|
| Bone Marrow Transplantation | 14 | 2009 | 135 | 0.850 |
Why?
|
| Major Histocompatibility Complex | 9 | 2010 | 86 | 0.830 |
Why?
|
| Flow Cytometry | 32 | 2016 | 638 | 0.820 |
Why?
|
| Cell Proliferation | 14 | 2024 | 943 | 0.800 |
Why?
|
| Insulin | 19 | 2024 | 689 | 0.790 |
Why?
|
| Hyperglycemia | 7 | 2014 | 104 | 0.770 |
Why?
|
| Communicable Diseases | 6 | 2016 | 83 | 0.760 |
Why?
|
| Prostheses and Implants | 6 | 2020 | 64 | 0.740 |
Why?
|
| CD4-Positive T-Lymphocytes | 27 | 2024 | 619 | 0.730 |
Why?
|
| Chimerism | 4 | 2016 | 10 | 0.710 |
Why?
|
| HIV-1 | 8 | 2018 | 709 | 0.700 |
Why?
|
| Lymphocytes | 12 | 2015 | 193 | 0.680 |
Why?
|
| Cytokines | 15 | 2023 | 909 | 0.670 |
Why?
|
| Models, Animal | 9 | 2021 | 221 | 0.670 |
Why?
|
| Immunologic Deficiency Syndromes | 8 | 2000 | 68 | 0.660 |
Why?
|
| Homeodomain Proteins | 7 | 2016 | 256 | 0.640 |
Why?
|
| Glucagon-Secreting Cells | 6 | 2024 | 26 | 0.640 |
Why?
|
| Male | 109 | 2024 | 27952 | 0.640 |
Why?
|
| Blood Transfusion | 12 | 2004 | 150 | 0.630 |
Why?
|
| Female | 115 | 2024 | 31234 | 0.620 |
Why?
|
| Foreign-Body Reaction | 6 | 2023 | 15 | 0.620 |
Why?
|
| Pancreas | 9 | 2018 | 146 | 0.620 |
Why?
|
| Poly I-C | 21 | 2013 | 74 | 0.610 |
Why?
|
| Bone Marrow | 15 | 2016 | 174 | 0.610 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2023 | 676 | 0.600 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 29 | 2013 | 106 | 0.590 |
Why?
|
| Morpholinos | 3 | 2013 | 50 | 0.590 |
Why?
|
| Cell Transplantation | 8 | 2020 | 39 | 0.590 |
Why?
|
| Adoptive Transfer | 15 | 2015 | 145 | 0.580 |
Why?
|
| Mice, Inbred CBA | 14 | 2007 | 82 | 0.570 |
Why?
|
| Neoplasms | 6 | 2023 | 1262 | 0.570 |
Why?
|
| Transplantation Conditioning | 8 | 2017 | 94 | 0.560 |
Why?
|
| Immunosuppressive Agents | 7 | 2020 | 303 | 0.550 |
Why?
|
| Transplantation Immunology | 6 | 2015 | 23 | 0.550 |
Why?
|
| Interferon-gamma | 17 | 2024 | 548 | 0.550 |
Why?
|
| Herpesvirus 4, Human | 2 | 2013 | 183 | 0.550 |
Why?
|
| Apoptosis | 13 | 2020 | 1040 | 0.540 |
Why?
|
| B-Lymphocytes | 14 | 2015 | 550 | 0.540 |
Why?
|
| Severe Combined Immunodeficiency | 5 | 2023 | 52 | 0.540 |
Why?
|
| Cytotoxicity, Immunologic | 14 | 2020 | 144 | 0.540 |
Why?
|
| Kidney | 7 | 2014 | 397 | 0.530 |
Why?
|
| Radiation Chimera | 9 | 2021 | 57 | 0.530 |
Why?
|
| Rats, Inbred Strains | 27 | 2010 | 152 | 0.530 |
Why?
|
| Immunotherapy | 7 | 2023 | 235 | 0.530 |
Why?
|
| Lipopolysaccharides | 8 | 2019 | 645 | 0.510 |
Why?
|
| Pluripotent Stem Cells | 6 | 2020 | 67 | 0.510 |
Why?
|
| Morpholines | 4 | 2016 | 85 | 0.510 |
Why?
|
| Radiation Tolerance | 4 | 2008 | 49 | 0.490 |
Why?
|
| Diabetes Mellitus | 9 | 2020 | 538 | 0.480 |
Why?
|
| Mutation | 8 | 2017 | 2466 | 0.480 |
Why?
|
| Lymphocyte Transfusion | 10 | 2003 | 37 | 0.480 |
Why?
|
| Liver | 10 | 2024 | 788 | 0.470 |
Why?
|
| Macrophages | 16 | 2024 | 1012 | 0.470 |
Why?
|
| Antigens, CD | 11 | 2019 | 343 | 0.460 |
Why?
|
| Stem Cell Factor | 4 | 2016 | 26 | 0.460 |
Why?
|
| HLA-A2 Antigen | 6 | 2015 | 65 | 0.460 |
Why?
|
| Mercuric Chloride | 5 | 2003 | 6 | 0.450 |
Why?
|
| T-Lymphocytes, Regulatory | 10 | 2015 | 199 | 0.450 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 3 | 2008 | 8 | 0.450 |
Why?
|
| Receptor, Interferon alpha-beta | 3 | 2009 | 45 | 0.450 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2013 | 92 | 0.440 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2013 | 137 | 0.440 |
Why?
|
| Tumor Necrosis Factor-alpha | 8 | 2011 | 584 | 0.430 |
Why?
|
| Brugia malayi | 6 | 1996 | 23 | 0.430 |
Why?
|
| Mice, Mutant Strains | 13 | 2014 | 304 | 0.430 |
Why?
|
| CD40 Antigens | 11 | 2006 | 60 | 0.420 |
Why?
|
| HIV Infections | 8 | 2018 | 927 | 0.420 |
Why?
|
| Chimera | 4 | 2007 | 42 | 0.410 |
Why?
|
| Cells, Cultured | 28 | 2020 | 2100 | 0.400 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2019 | 225 | 0.400 |
Why?
|
| Immunophenotyping | 15 | 2015 | 185 | 0.390 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2021 | 49 | 0.390 |
Why?
|
| Lymph Nodes | 15 | 2018 | 213 | 0.390 |
Why?
|
| Immunotherapy, Adoptive | 11 | 2016 | 86 | 0.380 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2021 | 184 | 0.380 |
Why?
|
| Neoplastic Stem Cells | 6 | 2016 | 203 | 0.380 |
Why?
|
| Laminin | 4 | 2015 | 76 | 0.380 |
Why?
|
| Leukocyte Transfusion | 4 | 2010 | 13 | 0.380 |
Why?
|
| Toll-Like Receptor 4 | 4 | 2023 | 348 | 0.380 |
Why?
|
| Filariasis | 5 | 2007 | 22 | 0.380 |
Why?
|
| Hepatocytes | 5 | 2017 | 194 | 0.380 |
Why?
|
| T-Lymphocytes, Cytotoxic | 8 | 2015 | 165 | 0.370 |
Why?
|
| Dengue Virus | 4 | 2014 | 95 | 0.370 |
Why?
|
| Rats, Inbred Lew | 27 | 2023 | 110 | 0.370 |
Why?
|
| RNA, Small Interfering | 11 | 2021 | 855 | 0.370 |
Why?
|
| Parvovirus | 7 | 2013 | 24 | 0.360 |
Why?
|
| Cell Line, Tumor | 14 | 2021 | 1381 | 0.360 |
Why?
|
| Interferon Type I | 3 | 2009 | 168 | 0.360 |
Why?
|
| Research | 2 | 2014 | 190 | 0.350 |
Why?
|
| Cell Line | 18 | 2018 | 2015 | 0.350 |
Why?
|
| Biocompatible Materials | 3 | 2023 | 142 | 0.350 |
Why?
|
| Glucagon | 4 | 2024 | 34 | 0.350 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 8 | 2012 | 112 | 0.340 |
Why?
|
| Disease | 1 | 2010 | 26 | 0.340 |
Why?
|
| Phenotype | 19 | 2018 | 1158 | 0.340 |
Why?
|
| Epitopes, T-Lymphocyte | 5 | 2024 | 177 | 0.340 |
Why?
|
| Peptide Nucleic Acids | 3 | 2016 | 17 | 0.340 |
Why?
|
| Autoantibodies | 9 | 2003 | 175 | 0.330 |
Why?
|
| Transcription Factors | 8 | 2018 | 1459 | 0.330 |
Why?
|
| Foreign Bodies | 2 | 2023 | 46 | 0.330 |
Why?
|
| Animals, Newborn | 11 | 2012 | 230 | 0.320 |
Why?
|
| Gene Expression Regulation | 11 | 2018 | 1541 | 0.320 |
Why?
|
| Prediabetic State | 3 | 2023 | 52 | 0.320 |
Why?
|
| Mice, Inbred C3H | 9 | 2008 | 174 | 0.320 |
Why?
|
| Skin | 1 | 2012 | 356 | 0.310 |
Why?
|
| Genetic Markers | 5 | 2004 | 122 | 0.300 |
Why?
|
| Lymphopenia | 6 | 2004 | 35 | 0.300 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 2 | 2019 | 28 | 0.300 |
Why?
|
| DNA | 7 | 2016 | 793 | 0.300 |
Why?
|
| Stromal Cells | 4 | 2020 | 65 | 0.300 |
Why?
|
| Parvoviridae Infections | 5 | 2010 | 23 | 0.300 |
Why?
|
| Antigens, Surface | 15 | 2011 | 192 | 0.300 |
Why?
|
| Bone Marrow Cells | 11 | 2004 | 232 | 0.290 |
Why?
|
| Dendritic Cells | 9 | 2016 | 508 | 0.290 |
Why?
|
| Mast Cells | 2 | 2019 | 41 | 0.290 |
Why?
|
| Leukocyte Common Antigens | 9 | 2010 | 55 | 0.290 |
Why?
|
| Blood Glucose | 8 | 2016 | 474 | 0.290 |
Why?
|
| Anaphylaxis | 2 | 2019 | 40 | 0.290 |
Why?
|
| Chromosome Mapping | 7 | 2009 | 293 | 0.280 |
Why?
|
| Membrane Proteins | 8 | 2020 | 844 | 0.280 |
Why?
|
| Insulin Resistance | 2 | 2024 | 407 | 0.280 |
Why?
|
| Antigens, Differentiation | 6 | 2000 | 141 | 0.280 |
Why?
|
| Graft Enhancement, Immunologic | 2 | 2006 | 10 | 0.270 |
Why?
|
| Interleukin-12 | 3 | 2024 | 123 | 0.270 |
Why?
|
| Research Support as Topic | 1 | 2007 | 44 | 0.270 |
Why?
|
| Dexamethasone | 3 | 2021 | 197 | 0.270 |
Why?
|
| Education | 1 | 2007 | 74 | 0.270 |
Why?
|
| Fetal Blood | 5 | 2009 | 70 | 0.270 |
Why?
|
| Interleukin-2 | 6 | 2015 | 164 | 0.270 |
Why?
|
| Poly(ADP-ribose) Polymerases | 5 | 2001 | 31 | 0.260 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2024 | 115 | 0.260 |
Why?
|
| Receptors, Antigen, T-Cell | 8 | 2016 | 280 | 0.260 |
Why?
|
| Zebrafish | 2 | 2024 | 323 | 0.260 |
Why?
|
| Stem Cells | 3 | 2016 | 258 | 0.260 |
Why?
|
| Cell Movement | 4 | 2017 | 425 | 0.260 |
Why?
|
| Heterografts | 5 | 2020 | 62 | 0.260 |
Why?
|
| Growth Inhibitors | 1 | 2006 | 27 | 0.260 |
Why?
|
| Cell Separation | 4 | 2023 | 147 | 0.260 |
Why?
|
| Time Factors | 19 | 2010 | 3612 | 0.260 |
Why?
|
| Lymphocytic Choriomeningitis | 3 | 2003 | 51 | 0.260 |
Why?
|
| Models, Biological | 9 | 2020 | 1142 | 0.250 |
Why?
|
| Rats, Nude | 8 | 2001 | 25 | 0.250 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2016 | 484 | 0.240 |
Why?
|
| Transcriptome | 2 | 2019 | 337 | 0.240 |
Why?
|
| Elephantiasis, Filarial | 3 | 1994 | 9 | 0.240 |
Why?
|
| Immunoconjugates | 3 | 2000 | 84 | 0.240 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 9 | 2014 | 449 | 0.240 |
Why?
|
| Injections, Intravenous | 6 | 2016 | 148 | 0.240 |
Why?
|
| Fibrosis | 3 | 2023 | 152 | 0.240 |
Why?
|
| CD4 Antigens | 5 | 2013 | 156 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2014 | 99 | 0.240 |
Why?
|
| Rats, Inbred WF | 20 | 2004 | 56 | 0.240 |
Why?
|
| Genes, RAG-1 | 2 | 2004 | 8 | 0.230 |
Why?
|
| Hydrogels | 2 | 2016 | 110 | 0.230 |
Why?
|
| Gene Expression Profiling | 3 | 2023 | 713 | 0.230 |
Why?
|
| Immunogenetics | 1 | 2004 | 4 | 0.230 |
Why?
|
| Genetic Linkage | 6 | 2009 | 101 | 0.220 |
Why?
|
| Crosses, Genetic | 9 | 2010 | 105 | 0.220 |
Why?
|
| Integrin alpha6beta1 | 2 | 2015 | 34 | 0.220 |
Why?
|
| CD8 Antigens | 9 | 2003 | 53 | 0.220 |
Why?
|
| Salmonella | 1 | 2024 | 37 | 0.220 |
Why?
|
| Neutrophils | 3 | 2016 | 351 | 0.220 |
Why?
|
| Virus Diseases | 3 | 2009 | 111 | 0.220 |
Why?
|
| Lymphoid Tissue | 6 | 2003 | 55 | 0.220 |
Why?
|
| Fatty Liver | 1 | 2024 | 97 | 0.210 |
Why?
|
| Sialadenitis | 3 | 1991 | 3 | 0.210 |
Why?
|
| Submandibular Gland | 3 | 1991 | 5 | 0.210 |
Why?
|
| Colonic Neoplasms | 2 | 2016 | 215 | 0.210 |
Why?
|
| Amines | 2 | 2015 | 30 | 0.210 |
Why?
|
| Cell Culture Techniques | 3 | 2016 | 178 | 0.210 |
Why?
|
| Aging | 9 | 2017 | 731 | 0.210 |
Why?
|
| Genetic Therapy | 4 | 2017 | 744 | 0.210 |
Why?
|
| Proteins | 5 | 2011 | 743 | 0.200 |
Why?
|
| Obesity | 2 | 2024 | 1190 | 0.200 |
Why?
|
| Interleukin-15 | 1 | 2022 | 22 | 0.200 |
Why?
|
| Gene Regulatory Networks | 1 | 2023 | 139 | 0.200 |
Why?
|
| Autoantigens | 3 | 2024 | 125 | 0.200 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2014 | 196 | 0.190 |
Why?
|
| Second Messenger Systems | 2 | 2021 | 26 | 0.190 |
Why?
|
| Genome-Wide Association Study | 2 | 2023 | 324 | 0.190 |
Why?
|
| Carrier Proteins | 4 | 2015 | 710 | 0.190 |
Why?
|
| Immunity, Cellular | 5 | 2018 | 176 | 0.190 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2018 | 56 | 0.190 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 2002 | 57 | 0.190 |
Why?
|
| HLA Antigens | 2 | 2011 | 60 | 0.190 |
Why?
|
| Whole-Body Irradiation | 5 | 2009 | 31 | 0.190 |
Why?
|
| Adenocarcinoma | 2 | 2016 | 327 | 0.190 |
Why?
|
| Cell Division | 11 | 2003 | 443 | 0.190 |
Why?
|
| Indium Radioisotopes | 2 | 2012 | 41 | 0.180 |
Why?
|
| Clonal Anergy | 3 | 2009 | 23 | 0.180 |
Why?
|
| Genetic Vectors | 3 | 2017 | 820 | 0.180 |
Why?
|
| Calcineurin | 2 | 2020 | 42 | 0.180 |
Why?
|
| Prostatic Neoplasms | 2 | 2016 | 330 | 0.180 |
Why?
|
| RNA, Messenger | 8 | 2017 | 1472 | 0.180 |
Why?
|
| Dinoprostone | 1 | 2021 | 44 | 0.180 |
Why?
|
| Serpins | 1 | 2020 | 17 | 0.180 |
Why?
|
| Toll-Like Receptor 3 | 4 | 2008 | 67 | 0.180 |
Why?
|
| Immunoglobulins | 7 | 2005 | 76 | 0.180 |
Why?
|
| Lymphocytic choriomeningitis virus | 3 | 2010 | 83 | 0.180 |
Why?
|
| Blotting, Western | 8 | 2016 | 597 | 0.180 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2017 | 83 | 0.180 |
Why?
|
| Antigen-Presenting Cells | 5 | 2010 | 176 | 0.180 |
Why?
|
| Liver Neoplasms | 2 | 2015 | 279 | 0.180 |
Why?
|
| Glucosides | 1 | 2020 | 13 | 0.180 |
Why?
|
| Pentetic Acid | 2 | 2010 | 32 | 0.180 |
Why?
|
| Gene Transfer Techniques | 3 | 2012 | 307 | 0.170 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2021 | 182 | 0.170 |
Why?
|
| Cyclic AMP | 1 | 2021 | 143 | 0.170 |
Why?
|
| Triazoles | 3 | 2016 | 53 | 0.170 |
Why?
|
| Species Specificity | 10 | 2020 | 335 | 0.170 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2000 | 35 | 0.170 |
Why?
|
| Dependovirus | 2 | 2017 | 659 | 0.170 |
Why?
|
| Endocrine Cells | 1 | 2019 | 10 | 0.170 |
Why?
|
| Pancreatitis | 2 | 2017 | 102 | 0.170 |
Why?
|
| Tacrolimus | 1 | 2020 | 39 | 0.170 |
Why?
|
| Benzhydryl Compounds | 1 | 2020 | 48 | 0.170 |
Why?
|
| beta 2-Microglobulin | 6 | 2010 | 47 | 0.170 |
Why?
|
| Lectins | 2 | 2019 | 38 | 0.170 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 2019 | 24 | 0.170 |
Why?
|
| Sirolimus | 1 | 2020 | 77 | 0.160 |
Why?
|
| Tissue Distribution | 5 | 2015 | 285 | 0.160 |
Why?
|
| CD4-CD8 Ratio | 3 | 2003 | 16 | 0.160 |
Why?
|
| Eosinophils | 1 | 2019 | 53 | 0.160 |
Why?
|
| Salmonella Infections | 1 | 2019 | 38 | 0.160 |
Why?
|
| Wound Healing | 2 | 2011 | 177 | 0.160 |
Why?
|
| Breast Neoplasms | 4 | 2020 | 1132 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 1999 | 6 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2017 | 60 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 1999 | 17 | 0.160 |
Why?
|
| Endothelium, Lymphatic | 1 | 2018 | 5 | 0.160 |
Why?
|
| Immune System Diseases | 1 | 2019 | 17 | 0.160 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2009 | 61 | 0.160 |
Why?
|
| Complement System Proteins | 2 | 2017 | 127 | 0.160 |
Why?
|
| Cell Survival | 9 | 2021 | 558 | 0.160 |
Why?
|
| Antigens | 4 | 2010 | 146 | 0.160 |
Why?
|
| Multigene Family | 1 | 1999 | 93 | 0.160 |
Why?
|
| Neutrophil Infiltration | 2 | 2016 | 61 | 0.160 |
Why?
|
| Gene Editing | 3 | 2018 | 301 | 0.150 |
Why?
|
| Specific Pathogen-Free Organisms | 4 | 2014 | 43 | 0.150 |
Why?
|
| Streptavidin | 2 | 2015 | 32 | 0.150 |
Why?
|
| Dengue | 4 | 2014 | 93 | 0.150 |
Why?
|
| Inflammation | 5 | 2023 | 1110 | 0.150 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 4 | 1999 | 109 | 0.150 |
Why?
|
| Neoplasm Transplantation | 3 | 2015 | 160 | 0.150 |
Why?
|
| Biotin | 2 | 2015 | 52 | 0.150 |
Why?
|
| Lymphopoiesis | 3 | 2008 | 25 | 0.150 |
Why?
|
| RNA | 3 | 2023 | 405 | 0.150 |
Why?
|
| CD28 Antigens | 4 | 2013 | 59 | 0.150 |
Why?
|
| Sequence Analysis, RNA | 2 | 2016 | 157 | 0.150 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2015 | 325 | 0.150 |
Why?
|
| Stem Cell Transplantation | 1 | 2018 | 75 | 0.150 |
Why?
|
| Leukocyte Count | 5 | 2015 | 94 | 0.150 |
Why?
|
| Tissue Donors | 7 | 2018 | 133 | 0.150 |
Why?
|
| Organ Culture Techniques | 5 | 2003 | 70 | 0.150 |
Why?
|
| Drug Delivery Systems | 1 | 2021 | 312 | 0.150 |
Why?
|
| Ligands | 5 | 2015 | 422 | 0.150 |
Why?
|
| Neovascularization, Pathologic | 1 | 2018 | 138 | 0.150 |
Why?
|
| Precision Medicine | 1 | 2019 | 105 | 0.150 |
Why?
|
| Isoantibodies | 3 | 1996 | 32 | 0.150 |
Why?
|
| HIV Antibodies | 1 | 2018 | 141 | 0.150 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2018 | 139 | 0.150 |
Why?
|
| Myeloid Differentiation Factor 88 | 2 | 2009 | 207 | 0.140 |
Why?
|
| Azepines | 2 | 2014 | 19 | 0.140 |
Why?
|
| Recombinant Proteins | 7 | 2017 | 696 | 0.140 |
Why?
|
| Receptors, CCR5 | 3 | 2013 | 57 | 0.140 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 105 | 0.140 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2017 | 23 | 0.140 |
Why?
|
| Endoplasmic Reticulum Stress | 2 | 2020 | 38 | 0.140 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2009 | 148 | 0.140 |
Why?
|
| Models, Immunological | 2 | 2011 | 79 | 0.140 |
Why?
|
| Endoplasmic Reticulum | 2 | 2009 | 168 | 0.140 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 8 | 0.140 |
Why?
|
| Enzyme Inhibitors | 2 | 2014 | 346 | 0.140 |
Why?
|
| Isotope Labeling | 3 | 2012 | 68 | 0.140 |
Why?
|
| DNA Nucleotidylexotransferase | 7 | 1994 | 11 | 0.140 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2017 | 15 | 0.140 |
Why?
|
| Combined Modality Therapy | 6 | 2004 | 360 | 0.140 |
Why?
|
| Lentivirus | 2 | 2015 | 62 | 0.140 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2017 | 48 | 0.140 |
Why?
|
| Carotid Artery Injuries | 1 | 2016 | 12 | 0.140 |
Why?
|
| Transgenes | 1 | 2017 | 176 | 0.140 |
Why?
|
| beta-Thalassemia | 1 | 2016 | 13 | 0.140 |
Why?
|
| Recurrence | 5 | 2014 | 600 | 0.140 |
Why?
|
| Stress, Physiological | 2 | 2009 | 186 | 0.140 |
Why?
|
| HLA-B27 Antigen | 1 | 2016 | 2 | 0.140 |
Why?
|
| Lysosomal Storage Diseases | 1 | 2016 | 14 | 0.140 |
Why?
|
| Receptors, KIR3DL1 | 1 | 2016 | 5 | 0.140 |
Why?
|
| Adenosine Triphosphatases | 1 | 2018 | 253 | 0.140 |
Why?
|
| Calcium Channels, L-Type | 1 | 2016 | 25 | 0.130 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2017 | 88 | 0.130 |
Why?
|
| Antigens, CD34 | 3 | 2016 | 53 | 0.130 |
Why?
|
| Vascular System Injuries | 1 | 2016 | 19 | 0.130 |
Why?
|
| Lymphoma | 6 | 2005 | 100 | 0.130 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2017 | 63 | 0.130 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2016 | 60 | 0.130 |
Why?
|
| MafB Transcription Factor | 1 | 2016 | 5 | 0.130 |
Why?
|
| Antibodies, Viral | 3 | 2014 | 303 | 0.130 |
Why?
|
| Passive Cutaneous Anaphylaxis | 1 | 2016 | 6 | 0.130 |
Why?
|
| GTP-Binding Proteins | 2 | 2009 | 80 | 0.130 |
Why?
|
| Longevity | 4 | 2005 | 112 | 0.130 |
Why?
|
| Base Sequence | 9 | 2013 | 1311 | 0.130 |
Why?
|
| Drug Resistance, Multiple | 1 | 2016 | 34 | 0.130 |
Why?
|
| Rats, Inbred BN | 7 | 2003 | 25 | 0.130 |
Why?
|
| Fetus | 2 | 2015 | 97 | 0.130 |
Why?
|
| C-Peptide | 1 | 2016 | 23 | 0.130 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2015 | 630 | 0.130 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 1 | 1 | 2015 | 5 | 0.130 |
Why?
|
| Retroviridae Infections | 1 | 2015 | 12 | 0.130 |
Why?
|
| Hematologic Neoplasms | 1 | 2016 | 45 | 0.130 |
Why?
|
| Salmonella typhimurium | 1 | 2016 | 80 | 0.130 |
Why?
|
| Osteogenesis | 1 | 2017 | 150 | 0.130 |
Why?
|
| Femoral Artery | 1 | 2016 | 94 | 0.130 |
Why?
|
| Atrophy | 1 | 1996 | 68 | 0.130 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 2015 | 197 | 0.130 |
Why?
|
| Single-Cell Analysis | 1 | 2016 | 92 | 0.130 |
Why?
|
| Leukemia Virus, Murine | 1 | 2015 | 30 | 0.130 |
Why?
|
| Brugia | 2 | 1992 | 4 | 0.130 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2015 | 41 | 0.130 |
Why?
|
| Alginates | 1 | 2016 | 44 | 0.130 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2016 | 60 | 0.130 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 327 | 0.120 |
Why?
|
| Genes, MHC Class II | 2 | 2018 | 36 | 0.120 |
Why?
|
| Genes, MHC Class I | 2 | 2018 | 28 | 0.120 |
Why?
|
| Adaptive Immunity | 2 | 2013 | 94 | 0.120 |
Why?
|
| Somatostatin-Secreting Cells | 1 | 2015 | 8 | 0.120 |
Why?
|
| Biomedical Research | 2 | 2008 | 251 | 0.120 |
Why?
|
| Nerve Tissue Proteins | 2 | 2015 | 417 | 0.120 |
Why?
|
| Immunocompetence | 3 | 2016 | 21 | 0.120 |
Why?
|
| Gene Targeting | 2 | 2012 | 82 | 0.120 |
Why?
|
| Antibody Specificity | 3 | 2012 | 99 | 0.120 |
Why?
|
| Cholesterol | 1 | 2016 | 255 | 0.120 |
Why?
|
| Organ Transplantation | 1 | 2015 | 51 | 0.120 |
Why?
|
| Lectins, C-Type | 3 | 2013 | 78 | 0.120 |
Why?
|
| Esters | 1 | 2015 | 19 | 0.120 |
Why?
|
| Triglycerides | 1 | 2016 | 242 | 0.120 |
Why?
|
| Ultrasonography | 1 | 2017 | 460 | 0.120 |
Why?
|
| RNA-Binding Proteins | 2 | 2015 | 388 | 0.120 |
Why?
|
| Intestinal Mucosa | 3 | 2004 | 225 | 0.120 |
Why?
|
| Coxsackievirus Infections | 1 | 2014 | 12 | 0.120 |
Why?
|
| Immunoglobulin M | 2 | 2014 | 112 | 0.120 |
Why?
|
| Embryonic Stem Cells | 1 | 2016 | 151 | 0.120 |
Why?
|
| Chromatin | 2 | 2023 | 598 | 0.120 |
Why?
|
| GABA Agents | 1 | 2014 | 3 | 0.120 |
Why?
|
| Cricetinae | 4 | 2013 | 376 | 0.120 |
Why?
|
| RNA Interference | 3 | 2021 | 593 | 0.120 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 2013 | 59 | 0.120 |
Why?
|
| Bowman Capsule | 1 | 2014 | 2 | 0.120 |
Why?
|
| Macrophage Activation | 2 | 2011 | 119 | 0.120 |
Why?
|
| Virus Internalization | 1 | 2015 | 99 | 0.120 |
Why?
|
| Immunization, Passive | 8 | 1995 | 100 | 0.120 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2015 | 59 | 0.120 |
Why?
|
| HEK293 Cells | 2 | 2020 | 578 | 0.120 |
Why?
|
| Integrin alpha6 | 1 | 2014 | 19 | 0.110 |
Why?
|
| Nanoparticles | 3 | 2018 | 499 | 0.110 |
Why?
|
| Kidney Diseases | 1 | 1996 | 160 | 0.110 |
Why?
|
| Nuclear Proteins | 3 | 2014 | 761 | 0.110 |
Why?
|
| Antibodies, Blocking | 3 | 2003 | 40 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 3 | 2021 | 118 | 0.110 |
Why?
|
| Immunohistochemistry | 5 | 2018 | 852 | 0.110 |
Why?
|
| Salicylates | 1 | 2013 | 9 | 0.110 |
Why?
|
| Yttrium Radioisotopes | 1 | 2013 | 7 | 0.110 |
Why?
|
| Extracellular Matrix | 1 | 2015 | 131 | 0.110 |
Why?
|
| Transduction, Genetic | 1 | 2015 | 233 | 0.110 |
Why?
|
| Disease Susceptibility | 8 | 2007 | 157 | 0.110 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2014 | 79 | 0.110 |
Why?
|
| Induction Chemotherapy | 1 | 2014 | 33 | 0.110 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2014 | 65 | 0.110 |
Why?
|
| Interleukin-4 | 6 | 2009 | 141 | 0.110 |
Why?
|
| Fluorescent Antibody Technique | 8 | 2016 | 218 | 0.110 |
Why?
|
| Lymphocyte Count | 4 | 2004 | 70 | 0.110 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2014 | 67 | 0.110 |
Why?
|
| Alleles | 6 | 2012 | 424 | 0.110 |
Why?
|
| Immunoglobulin G | 3 | 2009 | 453 | 0.110 |
Why?
|
| Mycobacterium bovis | 1 | 2013 | 27 | 0.110 |
Why?
|
| Metal Nanoparticles | 1 | 2016 | 181 | 0.110 |
Why?
|
| Testosterone | 1 | 1994 | 111 | 0.110 |
Why?
|
| Virulence | 3 | 2022 | 189 | 0.110 |
Why?
|
| Epitopes | 2 | 2012 | 295 | 0.110 |
Why?
|
| Child | 5 | 2021 | 4333 | 0.110 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2013 | 113 | 0.110 |
Why?
|
| Biomarkers | 4 | 2023 | 1213 | 0.110 |
Why?
|
| Fas Ligand Protein | 1 | 2013 | 39 | 0.110 |
Why?
|
| Adult | 9 | 2020 | 15975 | 0.110 |
Why?
|
| Gallbladder | 1 | 2013 | 31 | 0.100 |
Why?
|
| Autocrine Communication | 1 | 2013 | 31 | 0.100 |
Why?
|
| Estradiol | 1 | 1994 | 244 | 0.100 |
Why?
|
| fas Receptor | 1 | 2013 | 54 | 0.100 |
Why?
|
| RNA Splicing | 1 | 2014 | 160 | 0.100 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 648 | 0.100 |
Why?
|
| Thioredoxins | 1 | 2012 | 15 | 0.100 |
Why?
|
| Lymphocyte Culture Test, Mixed | 3 | 2009 | 32 | 0.100 |
Why?
|
| Neuropilin-2 | 1 | 2013 | 39 | 0.100 |
Why?
|
| Sex Characteristics | 1 | 1994 | 198 | 0.100 |
Why?
|
| Lymphocyte Subsets | 7 | 1999 | 35 | 0.100 |
Why?
|
| Onchocerca | 1 | 1992 | 1 | 0.100 |
Why?
|
| Onchocerciasis | 1 | 1992 | 1 | 0.100 |
Why?
|
| Hematopoietic Cell Growth Factors | 1 | 1992 | 4 | 0.100 |
Why?
|
| Viral Load | 3 | 2014 | 229 | 0.100 |
Why?
|
| Glucose | 2 | 2015 | 446 | 0.100 |
Why?
|
| Primates | 3 | 2017 | 42 | 0.100 |
Why?
|
| Regenerative Medicine | 1 | 2011 | 18 | 0.100 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2012 | 83 | 0.100 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2012 | 123 | 0.100 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 465 | 0.100 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 2 | 2013 | 26 | 0.100 |
Why?
|
| Hematopoietic System | 1 | 1991 | 10 | 0.100 |
Why?
|
| Young Adult | 5 | 2020 | 4391 | 0.100 |
Why?
|
| Polymers | 2 | 2016 | 317 | 0.090 |
Why?
|
| NAD+ Nucleosidase | 2 | 2001 | 10 | 0.090 |
Why?
|
| Trisaccharides | 1 | 2011 | 9 | 0.090 |
Why?
|
| Pancreatic Ducts | 1 | 2011 | 30 | 0.090 |
Why?
|
| Galactosyltransferases | 1 | 2011 | 17 | 0.090 |
Why?
|
| B7-2 Antigen | 2 | 2003 | 32 | 0.090 |
Why?
|
| Antibodies, Helminth | 3 | 1995 | 10 | 0.090 |
Why?
|
| Phosphorus Compounds | 1 | 2010 | 2 | 0.090 |
Why?
|
| Receptors, Immunologic | 1 | 2011 | 177 | 0.090 |
Why?
|
| Thymectomy | 7 | 2000 | 34 | 0.090 |
Why?
|
| Glycolipids | 1 | 2011 | 45 | 0.090 |
Why?
|
| Chemical Fractionation | 1 | 2010 | 13 | 0.090 |
Why?
|
| Ischemic Postconditioning | 1 | 2010 | 3 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2023 | 1565 | 0.090 |
Why?
|
| Immunocompromised Host | 1 | 2011 | 96 | 0.090 |
Why?
|
| Haptoglobins | 1 | 2010 | 15 | 0.090 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 353 | 0.090 |
Why?
|
| MAP Kinase Signaling System | 1 | 2012 | 201 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2011 | 64 | 0.090 |
Why?
|
| CTLA-4 Antigen | 4 | 2013 | 68 | 0.090 |
Why?
|
| Immunoglobulin Variable Region | 2 | 2008 | 32 | 0.090 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1992 | 158 | 0.090 |
Why?
|
| Isothiocyanates | 1 | 2010 | 19 | 0.090 |
Why?
|
| Liposomes | 1 | 2011 | 100 | 0.090 |
Why?
|
| Secretory Vesicles | 1 | 2010 | 22 | 0.090 |
Why?
|
| Cell Count | 3 | 2003 | 129 | 0.090 |
Why?
|
| NAD | 3 | 2001 | 48 | 0.090 |
Why?
|
| Tuberculosis | 1 | 2013 | 268 | 0.090 |
Why?
|
| Embryo, Nonmammalian | 1 | 2010 | 169 | 0.090 |
Why?
|
| Leptin | 1 | 2010 | 78 | 0.090 |
Why?
|
| Histocytochemistry | 1 | 2010 | 48 | 0.090 |
Why?
|
| In Vitro Techniques | 5 | 2015 | 472 | 0.090 |
Why?
|
| Centrosome | 1 | 2010 | 72 | 0.080 |
Why?
|
| Interferon Inducers | 2 | 2007 | 10 | 0.080 |
Why?
|
| Adolescent | 4 | 2020 | 5955 | 0.080 |
Why?
|
| DNA Nucleotidyltransferases | 2 | 1986 | 6 | 0.080 |
Why?
|
| Histocompatibility Antigens Class II | 3 | 2023 | 179 | 0.080 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2010 | 38 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 2 | 2011 | 35 | 0.080 |
Why?
|
| Regeneration | 3 | 1992 | 91 | 0.080 |
Why?
|
| Diet, High-Fat | 2 | 2024 | 160 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 5 | 2015 | 454 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 209 | 0.080 |
Why?
|
| Antibodies, Neutralizing | 3 | 2018 | 191 | 0.080 |
Why?
|
| Transcription Factor CHOP | 1 | 2009 | 6 | 0.080 |
Why?
|
| Etanercept | 1 | 2009 | 31 | 0.080 |
Why?
|
| Adenosine Diphosphate Ribose | 5 | 2006 | 15 | 0.080 |
Why?
|
| Solubility | 3 | 2001 | 176 | 0.080 |
Why?
|
| Galactosylceramides | 1 | 2009 | 11 | 0.080 |
Why?
|
| Cell Adhesion | 2 | 2003 | 209 | 0.080 |
Why?
|
| Radiopharmaceuticals | 1 | 2010 | 172 | 0.080 |
Why?
|
| Immunization | 1 | 2009 | 127 | 0.080 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2011 | 169 | 0.080 |
Why?
|
| Mercury | 3 | 1994 | 7 | 0.080 |
Why?
|
| Prognosis | 4 | 2017 | 1590 | 0.080 |
Why?
|
| Erythrocytes | 1 | 2010 | 154 | 0.080 |
Why?
|
| NF-kappa B | 3 | 2024 | 462 | 0.080 |
Why?
|
| Blood Cell Count | 3 | 2005 | 33 | 0.080 |
Why?
|
| Mice, Congenic | 1 | 2008 | 22 | 0.080 |
Why?
|
| Histocompatibility Testing | 2 | 2008 | 31 | 0.080 |
Why?
|
| DNA-Binding Proteins | 3 | 2019 | 1136 | 0.080 |
Why?
|
| Thy-1 Antigens | 5 | 1999 | 21 | 0.080 |
Why?
|
| Immunoblotting | 3 | 2012 | 190 | 0.080 |
Why?
|
| Thymus Neoplasms | 3 | 1995 | 21 | 0.080 |
Why?
|
| Inflammasomes | 1 | 2012 | 333 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2009 | 187 | 0.080 |
Why?
|
| Homozygote | 3 | 2003 | 116 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2010 | 525 | 0.080 |
Why?
|
| Oligonucleotides | 1 | 2010 | 211 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2023 | 1066 | 0.070 |
Why?
|
| Brugia pahangi | 1 | 2007 | 7 | 0.070 |
Why?
|
| Injections, Intraperitoneal | 3 | 2003 | 45 | 0.070 |
Why?
|
| Breeding | 2 | 2007 | 26 | 0.070 |
Why?
|
| Immunologic Memory | 4 | 2007 | 278 | 0.070 |
Why?
|
| Protein Kinase C | 1 | 2008 | 98 | 0.070 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2008 | 31 | 0.070 |
Why?
|
| Kinetics | 4 | 2002 | 735 | 0.070 |
Why?
|
| Cytotoxicity Tests, Immunologic | 3 | 2003 | 29 | 0.070 |
Why?
|
| Chromatin Immunoprecipitation | 3 | 2014 | 145 | 0.070 |
Why?
|
| Perforin | 2 | 2004 | 29 | 0.070 |
Why?
|
| Pore Forming Cytotoxic Proteins | 2 | 2004 | 33 | 0.070 |
Why?
|
| Liver Transplantation | 3 | 2016 | 193 | 0.070 |
Why?
|
| Cell Membrane | 3 | 2006 | 492 | 0.070 |
Why?
|
| Hemocyanins | 1 | 2006 | 23 | 0.070 |
Why?
|
| Point-of-Care Systems | 1 | 2008 | 123 | 0.070 |
Why?
|
| Health | 1 | 2007 | 32 | 0.070 |
Why?
|
| Poly Adenosine Diphosphate Ribose | 1 | 2006 | 3 | 0.070 |
Why?
|
| Sjogren's Syndrome | 1 | 1987 | 26 | 0.070 |
Why?
|
| Rats, Inbred BUF | 7 | 1992 | 10 | 0.070 |
Why?
|
| Caspase 3 | 2 | 2017 | 104 | 0.070 |
Why?
|
| Receptors, Interleukin-12 | 1 | 2006 | 9 | 0.070 |
Why?
|
| Gene Silencing | 3 | 2017 | 379 | 0.070 |
Why?
|
| Forkhead Transcription Factors | 1 | 2006 | 118 | 0.070 |
Why?
|
| Clonal Deletion | 1 | 2006 | 11 | 0.070 |
Why?
|
| Leukocytes | 1 | 2006 | 99 | 0.070 |
Why?
|
| Listeria monocytogenes | 1 | 1986 | 33 | 0.060 |
Why?
|
| Listeriosis | 1 | 1986 | 30 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2006 | 30 | 0.060 |
Why?
|
| Receptors, Interleukin | 1 | 2006 | 36 | 0.060 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2007 | 108 | 0.060 |
Why?
|
| Gene Deletion | 3 | 2020 | 298 | 0.060 |
Why?
|
| Career Choice | 1 | 2007 | 113 | 0.060 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2007 | 196 | 0.060 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 2 | 2002 | 8 | 0.060 |
Why?
|
| Homeostasis | 3 | 2014 | 343 | 0.060 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2005 | 16 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2005 | 14 | 0.060 |
Why?
|
| Receptors, Cell Surface | 2 | 2005 | 439 | 0.060 |
Why?
|
| Disease Progression | 2 | 2020 | 1054 | 0.060 |
Why?
|
| Abatacept | 3 | 2000 | 63 | 0.060 |
Why?
|
| Myelopoiesis | 1 | 2005 | 14 | 0.060 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2009 | 502 | 0.060 |
Why?
|
| Heart Transplantation | 2 | 2007 | 159 | 0.060 |
Why?
|
| Peptides | 3 | 2017 | 548 | 0.060 |
Why?
|
| Large Neutral Amino Acid-Transporter 1 | 1 | 2024 | 2 | 0.060 |
Why?
|
| Receptors, Glucagon | 1 | 2024 | 4 | 0.060 |
Why?
|
| B7-1 Antigen | 3 | 2003 | 73 | 0.060 |
Why?
|
| Coculture Techniques | 3 | 2017 | 94 | 0.060 |
Why?
|
| Antigens, Bacterial | 1 | 1986 | 212 | 0.060 |
Why?
|
| Macrophages, Peritoneal | 2 | 2011 | 73 | 0.060 |
Why?
|
| Antigen Presentation | 1 | 2006 | 228 | 0.060 |
Why?
|
| Inflammation Mediators | 2 | 2016 | 169 | 0.060 |
Why?
|
| Receptors, Interferon | 1 | 2024 | 19 | 0.060 |
Why?
|
| Fetal Tissue Transplantation | 2 | 2012 | 14 | 0.060 |
Why?
|
| Indoles | 2 | 2016 | 102 | 0.060 |
Why?
|
| Animals, Genetically Modified | 2 | 2018 | 281 | 0.060 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2024 | 51 | 0.060 |
Why?
|
| Phagocytosis | 2 | 2016 | 252 | 0.060 |
Why?
|
| Induced Pluripotent Stem Cells | 2 | 2017 | 137 | 0.060 |
Why?
|
| Technetium | 2 | 2015 | 68 | 0.060 |
Why?
|
| Middle Aged | 6 | 2020 | 16525 | 0.060 |
Why?
|
| Peptide Fragments | 2 | 2016 | 353 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2008 | 1315 | 0.060 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2003 | 9 | 0.060 |
Why?
|
| Pregnancy | 6 | 2015 | 2366 | 0.060 |
Why?
|
| Blood Cells | 1 | 2003 | 17 | 0.060 |
Why?
|
| Cell Lineage | 2 | 2002 | 250 | 0.060 |
Why?
|
| Myocardial Infarction | 1 | 2010 | 867 | 0.060 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2003 | 14 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2023 | 5259 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2016 | 200 | 0.050 |
Why?
|
| Glucose-6-Phosphatase | 2 | 2015 | 15 | 0.050 |
Why?
|
| CD5 Antigens | 2 | 2001 | 18 | 0.050 |
Why?
|
| Gene Expression | 3 | 2017 | 807 | 0.050 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2002 | 8 | 0.050 |
Why?
|
| Interleukin-18 | 1 | 2003 | 74 | 0.050 |
Why?
|
| Myeloid Cells | 1 | 2003 | 92 | 0.050 |
Why?
|
| Mitochondrial Proteins | 1 | 2003 | 99 | 0.050 |
Why?
|
| Enterovirus B, Human | 2 | 2014 | 17 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2024 | 162 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 2049 | 0.050 |
Why?
|
| Antigens, Ly | 1 | 2002 | 40 | 0.050 |
Why?
|
| Age Factors | 4 | 2004 | 1525 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2004 | 367 | 0.050 |
Why?
|
| Bacterial Proteins | 2 | 2019 | 751 | 0.050 |
Why?
|
| Isoenzymes | 2 | 2001 | 132 | 0.050 |
Why?
|
| Oligopeptides | 2 | 2015 | 130 | 0.050 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 2 | 2002 | 25 | 0.050 |
Why?
|
| Mice, Inbred Strains | 2 | 1996 | 182 | 0.050 |
Why?
|
| Convection | 1 | 2021 | 10 | 0.050 |
Why?
|
| Green Fluorescent Proteins | 2 | 2015 | 354 | 0.050 |
Why?
|
| Pyrophosphatases | 1 | 2001 | 11 | 0.050 |
Why?
|
| Monocytes | 1 | 2003 | 344 | 0.050 |
Why?
|
| Immunity, Mucosal | 1 | 2001 | 46 | 0.050 |
Why?
|
| Hybridization, Genetic | 2 | 1999 | 14 | 0.050 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 1 | 2021 | 5 | 0.050 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 1 | 2021 | 12 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2001 | 19 | 0.050 |
Why?
|
| Basophils | 2 | 2019 | 14 | 0.050 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2021 | 12 | 0.050 |
Why?
|
| Colforsin | 1 | 2021 | 24 | 0.050 |
Why?
|
| Chromogranins | 1 | 2021 | 12 | 0.050 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2001 | 20 | 0.050 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2021 | 27 | 0.050 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2021 | 46 | 0.050 |
Why?
|
| Granzymes | 1 | 2020 | 18 | 0.050 |
Why?
|
| Interleukin-6 | 3 | 2011 | 309 | 0.050 |
Why?
|
| Rats, Wistar | 2 | 2017 | 179 | 0.050 |
Why?
|
| Genome | 2 | 2004 | 253 | 0.040 |
Why?
|
| Hemolysis | 2 | 1998 | 38 | 0.040 |
Why?
|
| Peritoneal Cavity | 1 | 2000 | 31 | 0.040 |
Why?
|
| GPI-Linked Proteins | 2 | 1999 | 36 | 0.040 |
Why?
|
| Small Molecule Libraries | 1 | 2020 | 58 | 0.040 |
Why?
|
| DNA Primers | 3 | 2009 | 291 | 0.040 |
Why?
|
| Cell Line, Transformed | 1 | 2000 | 97 | 0.040 |
Why?
|
| Reproduction | 1 | 1980 | 88 | 0.040 |
Why?
|
| Erythrocyte Count | 1 | 2000 | 14 | 0.040 |
Why?
|
| Erythropoietin | 1 | 2020 | 34 | 0.040 |
Why?
|
| Permeability | 1 | 2020 | 49 | 0.040 |
Why?
|
| Mitochondria | 1 | 2003 | 337 | 0.040 |
Why?
|
| Interphase | 1 | 2000 | 68 | 0.040 |
Why?
|
| Capsules | 1 | 2020 | 32 | 0.040 |
Why?
|
| Protein Biosynthesis | 1 | 2002 | 297 | 0.040 |
Why?
|
| Immunity | 1 | 2020 | 97 | 0.040 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2019 | 12 | 0.040 |
Why?
|
| Genomic Islands | 1 | 2019 | 8 | 0.040 |
Why?
|
| Siderophores | 1 | 2019 | 11 | 0.040 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 2 | 1993 | 58 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 144 | 0.040 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2020 | 43 | 0.040 |
Why?
|
| Amino Acids, Aromatic | 1 | 2019 | 8 | 0.040 |
Why?
|
| THP-1 Cells | 1 | 2019 | 17 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2015 | 1850 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2014 | 190 | 0.040 |
Why?
|
| Mice, Obese | 1 | 2019 | 79 | 0.040 |
Why?
|
| Rodentia | 1 | 2019 | 20 | 0.040 |
Why?
|
| Mice, Inbred NZB | 2 | 1992 | 19 | 0.040 |
Why?
|
| Receptors, IgG | 1 | 2019 | 36 | 0.040 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 1999 | 11 | 0.040 |
Why?
|
| Chromatography, Liquid | 2 | 2016 | 120 | 0.040 |
Why?
|
| CD3 Complex | 3 | 2004 | 64 | 0.040 |
Why?
|
| RNA, Viral | 2 | 2012 | 265 | 0.040 |
Why?
|
| Bacterial Toxins | 1 | 2019 | 60 | 0.040 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2019 | 53 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 2 | 2014 | 663 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2021 | 277 | 0.040 |
Why?
|
| Theranostic Nanomedicine | 1 | 2018 | 6 | 0.040 |
Why?
|
| Coloring Agents | 1 | 1999 | 54 | 0.040 |
Why?
|
| Thyroid Gland | 2 | 1997 | 78 | 0.040 |
Why?
|
| Equipment Design | 1 | 2020 | 319 | 0.040 |
Why?
|
| Up-Regulation | 3 | 2008 | 365 | 0.040 |
Why?
|
| Iron | 1 | 2019 | 144 | 0.040 |
Why?
|
| Drug Compounding | 1 | 2019 | 75 | 0.040 |
Why?
|
| Neutralization Tests | 1 | 2018 | 125 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2019 | 111 | 0.040 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2010 | 82 | 0.040 |
Why?
|
| Pancreas Transplantation | 1 | 2018 | 21 | 0.040 |
Why?
|
| Lipoproteins, HDL | 1 | 1998 | 36 | 0.040 |
Why?
|
| Heat-Shock Proteins | 2 | 2009 | 66 | 0.040 |
Why?
|
| Serum Albumin | 2 | 2014 | 39 | 0.040 |
Why?
|
| Diethylcarbamazine | 1 | 1998 | 2 | 0.040 |
Why?
|
| Filaricides | 1 | 1998 | 2 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2018 | 91 | 0.040 |
Why?
|
| Thyroiditis | 3 | 1996 | 11 | 0.040 |
Why?
|
| Cellular Senescence | 1 | 1999 | 106 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2013 | 571 | 0.040 |
Why?
|
| Tetanus Toxoid | 1 | 1998 | 14 | 0.040 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 1998 | 10 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2018 | 74 | 0.040 |
Why?
|
| Cellular Reprogramming | 1 | 2018 | 33 | 0.040 |
Why?
|
| Molecular Chaperones | 2 | 2009 | 97 | 0.040 |
Why?
|
| Terminology as Topic | 1 | 1999 | 138 | 0.040 |
Why?
|
| Cyclin A1 | 1 | 2017 | 3 | 0.040 |
Why?
|
| Laser Therapy | 1 | 1998 | 36 | 0.040 |
Why?
|
| Forkhead Box Protein M1 | 1 | 2017 | 5 | 0.040 |
Why?
|
| NFATC Transcription Factors | 1 | 2017 | 20 | 0.040 |
Why?
|
| Venoms | 1 | 2017 | 11 | 0.040 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2017 | 18 | 0.040 |
Why?
|
| Protein Phosphatase 1 | 1 | 1997 | 16 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 1997 | 17 | 0.040 |
Why?
|
| Capillary Resistance | 1 | 2017 | 2 | 0.040 |
Why?
|
| Microscopy, Fluorescence | 2 | 2012 | 398 | 0.040 |
Why?
|
| Fucosyltransferases | 1 | 2017 | 4 | 0.040 |
Why?
|
| E-Selectin | 1 | 2017 | 18 | 0.040 |
Why?
|
| Microvessels | 1 | 2017 | 17 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 405 | 0.040 |
Why?
|
| Antigens, CD20 | 1 | 2017 | 14 | 0.040 |
Why?
|
| Periosteum | 1 | 2017 | 6 | 0.040 |
Why?
|
| Boston | 1 | 2018 | 336 | 0.030 |
Why?
|
| Milk Proteins | 1 | 1997 | 45 | 0.030 |
Why?
|
| Osteocalcin | 1 | 2017 | 48 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 1998 | 144 | 0.030 |
Why?
|
| Interleukin-1 | 2 | 1995 | 155 | 0.030 |
Why?
|
| Caseins | 1 | 1997 | 41 | 0.030 |
Why?
|
| Milk | 1 | 1997 | 51 | 0.030 |
Why?
|
| Melanocytes | 1 | 1998 | 78 | 0.030 |
Why?
|
| Vaccinia virus | 2 | 2009 | 71 | 0.030 |
Why?
|
| Collagen Type I | 1 | 2017 | 39 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2017 | 75 | 0.030 |
Why?
|
| Melanoma | 1 | 2020 | 334 | 0.030 |
Why?
|
| beta-Globins | 1 | 2016 | 9 | 0.030 |
Why?
|
| Glycosylation | 1 | 2017 | 135 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1997 | 130 | 0.030 |
Why?
|
| Genes | 2 | 1990 | 96 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 1998 | 171 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2009 | 454 | 0.030 |
Why?
|
| Rituximab | 1 | 2017 | 82 | 0.030 |
Why?
|
| Neointima | 1 | 2016 | 19 | 0.030 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2017 | 51 | 0.030 |
Why?
|
| Rats, Inbred F344 | 3 | 2011 | 52 | 0.030 |
Why?
|
| HLA-DR4 Antigen | 1 | 2016 | 9 | 0.030 |
Why?
|
| Leukemia, T-Cell | 1 | 1996 | 5 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2016 | 32 | 0.030 |
Why?
|
| PPAR gamma | 1 | 2017 | 73 | 0.030 |
Why?
|
| Glutamate Decarboxylase | 1 | 2016 | 23 | 0.030 |
Why?
|
| Mice, Inbred DBA | 3 | 2003 | 84 | 0.030 |
Why?
|
| Extracellular Space | 1 | 2016 | 30 | 0.030 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2017 | 87 | 0.030 |
Why?
|
| Microfluidics | 1 | 2016 | 22 | 0.030 |
Why?
|
| src-Family Kinases | 1 | 1996 | 60 | 0.030 |
Why?
|
| Th2 Cells | 2 | 2007 | 98 | 0.030 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2016 | 60 | 0.030 |
Why?
|
| Catalysis | 3 | 2006 | 154 | 0.030 |
Why?
|
| Rabbits | 2 | 2011 | 331 | 0.030 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2016 | 15 | 0.030 |
Why?
|
| Gene Library | 1 | 2016 | 99 | 0.030 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2016 | 33 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2016 | 99 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2016 | 90 | 0.030 |
Why?
|
| Glucose Clamp Technique | 1 | 2015 | 58 | 0.030 |
Why?
|
| Pyrroles | 1 | 2016 | 50 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2016 | 57 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2015 | 26 | 0.030 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 1 | 2015 | 6 | 0.030 |
Why?
|
| Immunoglobulin E | 1 | 2016 | 85 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 1996 | 196 | 0.030 |
Why?
|
| Lysosomes | 1 | 2016 | 163 | 0.030 |
Why?
|
| Thyroiditis, Autoimmune | 2 | 1997 | 8 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 2015 | 64 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2016 | 110 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2016 | 139 | 0.030 |
Why?
|
| Biotinylation | 1 | 2015 | 38 | 0.030 |
Why?
|
| Snail Family Transcription Factors | 1 | 2015 | 25 | 0.030 |
Why?
|
| Genetic Engineering | 1 | 2016 | 112 | 0.030 |
Why?
|
| Vitiligo | 1 | 1998 | 120 | 0.030 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2015 | 20 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2016 | 305 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2016 | 78 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2016 | 135 | 0.030 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2015 | 37 | 0.030 |
Why?
|
| Niacinamide | 1 | 2015 | 32 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2016 | 219 | 0.030 |
Why?
|
| Gonadal Steroid Hormones | 1 | 1995 | 32 | 0.030 |
Why?
|
| Extracellular Traps | 1 | 2015 | 40 | 0.030 |
Why?
|
| Succinimides | 1 | 2015 | 17 | 0.030 |
Why?
|
| Agammaglobulinemia | 1 | 1995 | 8 | 0.030 |
Why?
|
| Epidermal Growth Factor | 1 | 2015 | 48 | 0.030 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 1994 | 11 | 0.030 |
Why?
|
| Chelating Agents | 1 | 2015 | 46 | 0.030 |
Why?
|
| Jurkat Cells | 1 | 2015 | 102 | 0.030 |
Why?
|
| Cell Death | 1 | 2016 | 272 | 0.030 |
Why?
|
| Activins | 1 | 2015 | 54 | 0.030 |
Why?
|
| Organogenesis | 1 | 2015 | 40 | 0.030 |
Why?
|
| Capsid Proteins | 1 | 2015 | 93 | 0.030 |
Why?
|
| Genes, Dominant | 1 | 1994 | 56 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2016 | 118 | 0.030 |
Why?
|
| Dietary Fats | 1 | 2015 | 204 | 0.030 |
Why?
|
| Epithelium | 1 | 1994 | 97 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2015 | 248 | 0.030 |
Why?
|
| Immunoglobulin Isotypes | 1 | 1994 | 24 | 0.030 |
Why?
|
| Body Burden | 1 | 1994 | 12 | 0.030 |
Why?
|
| CD24 Antigen | 1 | 2014 | 17 | 0.030 |
Why?
|
| Transplantation, Heterotopic | 1 | 1994 | 7 | 0.030 |
Why?
|
| Swine | 2 | 2011 | 349 | 0.030 |
Why?
|
| Orchiectomy | 1 | 1994 | 28 | 0.030 |
Why?
|
| Hyaluronan Receptors | 1 | 2014 | 34 | 0.030 |
Why?
|
| Tissue Transplantation | 1 | 2014 | 9 | 0.030 |
Why?
|
| Streptozocin | 1 | 1994 | 21 | 0.030 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2014 | 31 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2014 | 54 | 0.030 |
Why?
|
| Reference Values | 1 | 1994 | 322 | 0.030 |
Why?
|
| Ovariectomy | 1 | 1994 | 97 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2014 | 38 | 0.030 |
Why?
|
| Gold | 1 | 2016 | 227 | 0.030 |
Why?
|
| Environment | 3 | 2008 | 125 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2015 | 293 | 0.030 |
Why?
|
| Hydrolases | 1 | 2014 | 80 | 0.030 |
Why?
|
| B7-H1 Antigen | 1 | 2014 | 53 | 0.030 |
Why?
|
| Receptor, Notch1 | 1 | 2014 | 61 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 661 | 0.030 |
Why?
|
| Protein Binding | 2 | 2009 | 1560 | 0.030 |
Why?
|
| Cricetulus | 1 | 2013 | 102 | 0.030 |
Why?
|
| Injections | 1 | 2013 | 79 | 0.030 |
Why?
|
| CHO Cells | 1 | 2013 | 190 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2015 | 290 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 192 | 0.030 |
Why?
|
| Clone Cells | 2 | 2004 | 106 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2013 | 113 | 0.030 |
Why?
|
| Schizophrenia | 1 | 2015 | 256 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2008 | 353 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2013 | 10 | 0.030 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2013 | 32 | 0.030 |
Why?
|
| Binding Sites, Antibody | 2 | 2011 | 29 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2015 | 350 | 0.030 |
Why?
|
| Vagina | 1 | 2013 | 83 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1994 | 130 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2002 | 807 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2015 | 295 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2013 | 136 | 0.030 |
Why?
|
| eIF-2 Kinase | 1 | 2012 | 10 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2016 | 743 | 0.030 |
Why?
|
| Dengue Vaccines | 1 | 2012 | 7 | 0.030 |
Why?
|
| Dose-Response Relationship, Immunologic | 3 | 1994 | 49 | 0.030 |
Why?
|
| Diet | 1 | 1997 | 637 | 0.030 |
Why?
|
| Hypersensitivity, Delayed | 2 | 2002 | 22 | 0.030 |
Why?
|
| Histological Techniques | 1 | 2012 | 18 | 0.030 |
Why?
|
| Molecular Sequence Data | 4 | 1997 | 1975 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2014 | 370 | 0.020 |
Why?
|
| Immunity, Humoral | 1 | 2012 | 41 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2013 | 194 | 0.020 |
Why?
|
| Microfilariae | 1 | 1992 | 2 | 0.020 |
Why?
|
| Luciferases | 1 | 2012 | 109 | 0.020 |
Why?
|
| Lod Score | 2 | 2004 | 26 | 0.020 |
Why?
|
| Microsatellite Repeats | 2 | 2004 | 37 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 3 | 1999 | 498 | 0.020 |
Why?
|
| Costimulatory and Inhibitory T-Cell Receptors | 1 | 2011 | 2 | 0.020 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2011 | 20 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 1992 | 74 | 0.020 |
Why?
|
| Pichinde virus | 2 | 2003 | 19 | 0.020 |
Why?
|
| CCR5 Receptor Antagonists | 1 | 2011 | 14 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 2 | 2004 | 54 | 0.020 |
Why?
|
| Codon, Terminator | 1 | 2011 | 21 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2013 | 238 | 0.020 |
Why?
|
| Mice, Nude | 1 | 1992 | 260 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2014 | 388 | 0.020 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2011 | 7 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2017 | 622 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2011 | 85 | 0.020 |
Why?
|
| Prealbumin | 1 | 2011 | 20 | 0.020 |
Why?
|
| DNA, Viral | 2 | 2007 | 228 | 0.020 |
Why?
|
| Liver Regeneration | 1 | 2011 | 17 | 0.020 |
Why?
|
| Virus Physiological Phenomena | 1 | 1991 | 7 | 0.020 |
Why?
|
| Diacylglycerol Kinase | 1 | 2011 | 10 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2011 | 52 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2012 | 132 | 0.020 |
Why?
|
| Phosphoenolpyruvate Carboxykinase (GTP) | 1 | 2010 | 5 | 0.020 |
Why?
|
| Picolinic Acids | 1 | 2010 | 7 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2010 | 39 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2012 | 262 | 0.020 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2010 | 26 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2015 | 678 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2010 | 56 | 0.020 |
Why?
|
| Histones | 1 | 2014 | 464 | 0.020 |
Why?
|
| Complement Activation | 1 | 2011 | 53 | 0.020 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2010 | 12 | 0.020 |
Why?
|
| Antibody Formation | 3 | 1993 | 111 | 0.020 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2012 | 256 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2011 | 125 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2010 | 215 | 0.020 |
Why?
|
| Fatty Acids, Essential | 1 | 1990 | 8 | 0.020 |
Why?
|
| Random Allocation | 1 | 2010 | 197 | 0.020 |
Why?
|
| Spinal Cord | 2 | 1993 | 197 | 0.020 |
Why?
|
| Recombination, Genetic | 2 | 1982 | 236 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2010 | 137 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2009 | 43 | 0.020 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2009 | 22 | 0.020 |
Why?
|
| Enterovirus Infections | 1 | 2009 | 11 | 0.020 |
Why?
|
| DNA Repair | 1 | 2011 | 233 | 0.020 |
Why?
|
| Abdomen | 1 | 2010 | 92 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2009 | 116 | 0.020 |
Why?
|
| Phylogeny | 1 | 2010 | 334 | 0.020 |
Why?
|
| Columbidae | 1 | 2009 | 11 | 0.020 |
Why?
|
| Cell Nucleus | 2 | 2008 | 603 | 0.020 |
Why?
|
| Embryonic Development | 1 | 2010 | 136 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2009 | 68 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2009 | 25 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2010 | 174 | 0.020 |
Why?
|
| Cytomegalovirus Infections | 1 | 2009 | 70 | 0.020 |
Why?
|
| Binding Sites | 1 | 2011 | 870 | 0.020 |
Why?
|
| Biological Factors | 1 | 1989 | 23 | 0.020 |
Why?
|
| Lung | 1 | 2013 | 841 | 0.020 |
Why?
|
| Antigens, CD7 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Phosphorylation | 2 | 2004 | 860 | 0.020 |
Why?
|
| Immunoglobulin Fragments | 1 | 2008 | 8 | 0.020 |
Why?
|
| Antigens, CD19 | 1 | 2008 | 20 | 0.020 |
Why?
|
| Pneumococcal Vaccines | 1 | 2008 | 20 | 0.020 |
Why?
|
| Haplotypes | 1 | 2009 | 117 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2009 | 193 | 0.020 |
Why?
|
| Phorbol 12,13-Dibutyrate | 1 | 2008 | 5 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 292 | 0.020 |
Why?
|
| Thapsigargin | 1 | 2008 | 17 | 0.020 |
Why?
|
| Ionomycin | 1 | 2008 | 15 | 0.020 |
Why?
|
| Heart | 1 | 2010 | 276 | 0.020 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Light Chain | 1 | 1988 | 5 | 0.020 |
Why?
|
| Virus Replication | 1 | 2009 | 306 | 0.020 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 1988 | 10 | 0.020 |
Why?
|
| Genes, Immunoglobulin | 1 | 1988 | 32 | 0.020 |
Why?
|
| Inducible T-Cell Co-Stimulator Ligand | 1 | 2007 | 4 | 0.020 |
Why?
|
| Mice, Inbred ICR | 1 | 2007 | 27 | 0.020 |
Why?
|
| Genotype | 1 | 2009 | 643 | 0.020 |
Why?
|
| Larva | 1 | 2007 | 128 | 0.020 |
Why?
|
| Spodoptera | 2 | 1997 | 27 | 0.020 |
Why?
|
| Transfection | 1 | 2009 | 676 | 0.020 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2007 | 16 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2006 | 11 | 0.020 |
Why?
|
| Chloroquine | 1 | 2007 | 49 | 0.020 |
Why?
|
| Fluoresceins | 1 | 2006 | 29 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 170 | 0.020 |
Why?
|
| Myelin Basic Protein | 1 | 1986 | 23 | 0.020 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2006 | 17 | 0.020 |
Why?
|
| Structural Homology, Protein | 1 | 2006 | 20 | 0.020 |
Why?
|
| Host vs Graft Reaction | 1 | 2006 | 3 | 0.020 |
Why?
|
| Subrenal Capsule Assay | 1 | 2006 | 3 | 0.020 |
Why?
|
| Genome, Viral | 1 | 2007 | 122 | 0.020 |
Why?
|
| Sex Factors | 1 | 2009 | 969 | 0.020 |
Why?
|
| Cattle | 2 | 1997 | 306 | 0.020 |
Why?
|
| AKR murine leukemia virus | 1 | 1985 | 1 | 0.020 |
Why?
|
| Leukemia, Experimental | 1 | 1985 | 19 | 0.020 |
Why?
|
| Prostaglandins E | 1 | 1985 | 8 | 0.020 |
Why?
|
| Arthritis | 1 | 2005 | 50 | 0.020 |
Why?
|
| Parvoviridae | 1 | 2005 | 5 | 0.020 |
Why?
|
| Thymidine | 2 | 1996 | 25 | 0.020 |
Why?
|
| Metrizamide | 1 | 2004 | 4 | 0.020 |
Why?
|
| Early Growth Response Protein 2 | 1 | 2004 | 8 | 0.020 |
Why?
|
| Collagen | 1 | 2005 | 119 | 0.020 |
Why?
|
| Graft vs Host Reaction | 2 | 1982 | 7 | 0.010 |
Why?
|
| Phytohemagglutinins | 2 | 1982 | 14 | 0.010 |
Why?
|
| Vaccinia | 1 | 2005 | 31 | 0.010 |
Why?
|
| Interleukins | 1 | 2005 | 78 | 0.010 |
Why?
|
| Oxidoreductases | 1 | 2005 | 65 | 0.010 |
Why?
|
| Body Weight | 2 | 1990 | 381 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2005 | 195 | 0.010 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2004 | 70 | 0.010 |
Why?
|
| Zinc Fingers | 1 | 2004 | 95 | 0.010 |
Why?
|
| Th1 Cells | 1 | 2005 | 175 | 0.010 |
Why?
|
| Radiation Hybrid Mapping | 1 | 2004 | 2 | 0.010 |
Why?
|
| Mosaicism | 1 | 1984 | 26 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 1996 | 183 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2003 | 35 | 0.010 |
Why?
|
| Lymphocytosis | 1 | 2003 | 3 | 0.010 |
Why?
|
| Drug Resistance | 2 | 1994 | 92 | 0.010 |
Why?
|
| Concanavalin A | 1 | 2003 | 40 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 2003 | 39 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2003 | 137 | 0.010 |
Why?
|
| Rats, Mutant Strains | 1 | 2002 | 10 | 0.010 |
Why?
|
| Cell Fractionation | 1 | 1982 | 31 | 0.010 |
Why?
|
| Immunodominant Epitopes | 1 | 2003 | 57 | 0.010 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2007 | 389 | 0.010 |
Why?
|
| Pancreatic Diseases | 1 | 2002 | 40 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2006 | 1129 | 0.010 |
Why?
|
| Chromosomes | 1 | 2004 | 135 | 0.010 |
Why?
|
| Caspases | 1 | 2003 | 164 | 0.010 |
Why?
|
| Immune Sera | 1 | 1982 | 35 | 0.010 |
Why?
|
| Interleukin-7 | 1 | 2002 | 30 | 0.010 |
Why?
|
| Hematoma | 1 | 1982 | 74 | 0.010 |
Why?
|
| Gamma Rays | 2 | 1994 | 31 | 0.010 |
Why?
|
| Phosphatidylinositol Diacylglycerol-Lyase | 1 | 2001 | 5 | 0.010 |
Why?
|
| H-2 Antigens | 1 | 2001 | 60 | 0.010 |
Why?
|
| Cholera Toxin | 1 | 2001 | 7 | 0.010 |
Why?
|
| Mitogens | 1 | 2001 | 10 | 0.010 |
Why?
|
| Phosphorus Radioisotopes | 1 | 2001 | 13 | 0.010 |
Why?
|
| Pertussis Toxin | 1 | 2001 | 14 | 0.010 |
Why?
|
| Virulence Factors, Bordetella | 1 | 2001 | 14 | 0.010 |
Why?
|
| Incidence | 2 | 1997 | 1261 | 0.010 |
Why?
|
| Adenosine Diphosphate | 1 | 2001 | 41 | 0.010 |
Why?
|
| Adenosine Monophosphate | 1 | 2001 | 24 | 0.010 |
Why?
|
| Type C Phospholipases | 1 | 2001 | 33 | 0.010 |
Why?
|
| Phosphoinositide Phospholipase C | 1 | 2001 | 32 | 0.010 |
Why?
|
| Immunoradiometric Assay | 1 | 2001 | 3 | 0.010 |
Why?
|
| Proinsulin | 1 | 2001 | 3 | 0.010 |
Why?
|
| Receptors, Transferrin | 1 | 2001 | 35 | 0.010 |
Why?
|
| Adenosine | 1 | 2001 | 69 | 0.010 |
Why?
|
| Litter Size | 1 | 1980 | 8 | 0.010 |
Why?
|
| Sex Ratio | 1 | 1980 | 9 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2001 | 53 | 0.010 |
Why?
|
| Growth | 1 | 1980 | 22 | 0.010 |
Why?
|
| Nucleotidyltransferases | 1 | 1981 | 54 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2001 | 98 | 0.010 |
Why?
|
| Adrenalectomy | 2 | 1994 | 24 | 0.010 |
Why?
|
| Organ Size | 1 | 1980 | 165 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2001 | 130 | 0.010 |
Why?
|
| Ovary | 1 | 1980 | 96 | 0.010 |
Why?
|
| Interleukin-3 | 1 | 2000 | 21 | 0.010 |
Why?
|
| Thrombopoietin | 1 | 2000 | 10 | 0.010 |
Why?
|
| Interleukin-11 | 1 | 2000 | 8 | 0.010 |
Why?
|
| Testis | 1 | 1980 | 138 | 0.010 |
Why?
|
| Cell Communication | 2 | 1993 | 127 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2001 | 558 | 0.010 |
Why?
|
| Povidone | 1 | 1999 | 8 | 0.010 |
Why?
|
| Age of Onset | 1 | 1999 | 171 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1999 | 35 | 0.010 |
Why?
|
| Peyer's Patches | 1 | 1999 | 35 | 0.010 |
Why?
|
| Silicon Dioxide | 1 | 1999 | 59 | 0.010 |
Why?
|
| Ultracentrifugation | 1 | 1998 | 28 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 1998 | 65 | 0.010 |
Why?
|
| Thioglycolates | 1 | 1998 | 7 | 0.010 |
Why?
|
| Aged | 1 | 2014 | 13580 | 0.010 |
Why?
|
| Nitrates | 1 | 1998 | 20 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 1998 | 46 | 0.010 |
Why?
|
| Intestine, Small | 1 | 1998 | 75 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1998 | 132 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1998 | 281 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 1998 | 71 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 1999 | 228 | 0.010 |
Why?
|
| Acute Disease | 1 | 1999 | 661 | 0.010 |
Why?
|
| Thyroglobulin | 1 | 1997 | 9 | 0.010 |
Why?
|
| Baculoviridae | 1 | 1997 | 26 | 0.010 |
Why?
|
| Xenobiotics | 1 | 1997 | 13 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1997 | 79 | 0.010 |
Why?
|
| Adrenal Glands | 1 | 1997 | 30 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2001 | 848 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1997 | 291 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1996 | 65 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 1999 | 376 | 0.010 |
Why?
|
| Cross-Linking Reagents | 1 | 1996 | 113 | 0.010 |
Why?
|
| Vesicular Transport Proteins | 1 | 1996 | 104 | 0.010 |
Why?
|
| Blood | 1 | 1994 | 27 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1996 | 345 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1997 | 1581 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 1993 | 50 | 0.010 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1993 | 72 | 0.010 |
Why?
|
| Killer Factors, Yeast | 1 | 1991 | 3 | 0.010 |
Why?
|
| Basement Membrane | 1 | 1991 | 25 | 0.010 |
Why?
|
| Azathioprine | 1 | 1991 | 23 | 0.010 |
Why?
|
| Causality | 1 | 1991 | 56 | 0.010 |
Why?
|
| Cyclosporine | 1 | 1991 | 57 | 0.010 |
Why?
|
| Prednisone | 1 | 1991 | 80 | 0.010 |
Why?
|
| Interferons | 1 | 1991 | 63 | 0.010 |
Why?
|
| Linoleic Acids | 1 | 1990 | 8 | 0.010 |
Why?
|
| Linoleic Acid | 1 | 1990 | 18 | 0.010 |
Why?
|
| Viruses | 1 | 1991 | 79 | 0.010 |
Why?
|
| Fatty Acids | 1 | 1990 | 194 | 0.000 |
Why?
|
| Ultraviolet Rays | 1 | 1989 | 125 | 0.000 |
Why?
|
| Blotting, Southern | 1 | 1988 | 52 | 0.000 |
Why?
|
| Acid Phosphatase | 1 | 1987 | 4 | 0.000 |
Why?
|
| Carboxylesterase | 1 | 1987 | 4 | 0.000 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 1987 | 11 | 0.000 |
Why?
|
| Organ Specificity | 1 | 1987 | 180 | 0.000 |
Why?
|
| Peanut Agglutinin | 1 | 1985 | 1 | 0.000 |
Why?
|
| Alprostadil | 1 | 1985 | 6 | 0.000 |
Why?
|
| Brain | 1 | 1993 | 1493 | 0.000 |
Why?
|
| Cytoplasm | 1 | 1985 | 274 | 0.000 |
Why?
|
| Hemolytic Plaque Technique | 1 | 1983 | 11 | 0.000 |
Why?
|
| Rats, Inbred ACI | 1 | 1983 | 6 | 0.000 |
Why?
|
| Hybrid Cells | 1 | 1983 | 19 | 0.000 |
Why?
|
| Antilymphocyte Serum | 1 | 1983 | 21 | 0.000 |
Why?
|
| Antibody-Producing Cells | 1 | 1983 | 13 | 0.000 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1979 | 12 | 0.000 |
Why?
|
| Lymphocyte Cooperation | 1 | 1979 | 30 | 0.000 |
Why?
|